Biohaven Pharmaceutical Holding is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Biohaven Pharmaceutical's Net Tangible Assets are very stable compared to the past year. As of the 27th of March 2025, Accumulated Other Comprehensive Income is likely to grow to about 86.2 K, while Total Assets are likely to drop about 388.4 M. Key indicators impacting Biohaven Pharmaceutical's financial strength include:
Investors should never underestimate Biohaven Pharmaceutical's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biohaven Pharmaceutical's cash flow, debt, and profitability to make informed and accurate decisions about investing in Biohaven Pharmaceutical Holding.
Net Income
(804.1 Million)
Biohaven
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Investments
Total Cashflows From Investing Activities
Depreciation
Change To Operating Activities
Issuance Of Capital Stock
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Short Long Term Debt Total
Other Liab
Net Tangible Assets
Current Deferred Revenue
Other Assets
Net Receivables
Short Term Investments
Inventory
Net Invested Capital
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Property Plant Equipment
Capital Lease Obligations
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Tax Provision
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Net Income Applicable To Common Shares
Probability Of Bankruptcy
Understanding current and past Biohaven Pharmaceutical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biohaven Pharmaceutical's financial statements are interrelated, with each one affecting the others. For example, an increase in Biohaven Pharmaceutical's assets may result in an increase in income on the income statement.
Biohaven Pharmaceutical competes with Immunome, Inhibrx, Day One, Terns Pharmaceuticals, and X4 Pharmaceuticals. Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. Biohaven is traded on New York Stock Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Biohaven Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Biohaven Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biohaven Pharmaceutical competition to find correlations between indicators driving Biohaven Pharmaceutical's intrinsic value. More Info.
Biohaven Pharmaceutical Holding is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Biohaven Pharmaceutical's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biohaven Pharmaceutical's earnings, one of the primary drivers of an investment's value.
Biohaven Pharmaceutical Systematic Risk
Biohaven Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biohaven Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Biohaven Pharmaceutical correlated with the market. If Beta is less than 0 Biohaven Pharmaceutical generally moves in the opposite direction as compared to the market. If Biohaven Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biohaven Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biohaven Pharmaceutical is generally in the same direction as the market. If Beta > 1 Biohaven Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Biohaven Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biohaven Pharmaceutical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biohaven Pharmaceutical growth as a starting point in their analysis.
Biohaven Pharmaceutical March 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biohaven Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biohaven Pharmaceutical Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biohaven Pharmaceutical Holding based on widely used predictive technical indicators. In general, we focus on analyzing Biohaven Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biohaven Pharmaceutical's daily price indicators and compare them against related drivers.
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.28)
Return On Assets
(0.97)
Return On Equity
(1.99)
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.